Foghorn Therapeutics Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Adrian Gottschalk (CEO) and Ryan Maynard (CFO) signed standard Sarbanes-Oxley Section 302 and 906 certifications dated August 6, 2026 for the quarter ended June 30, 2026. The certifications confirm the 10-Q contains no untrue statements, financial statements fairly present results, and disclosure controls and internal controls are effective. No specific operational changes, transactions, or material developments are described in these exhibit pages.
Why this rating
Routine SOX certifications. No operational facts disclosed. Standard periodic filing compliance matter; immaterial to business trajectory.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.